What this means
A trial will compare a four-week prehabilitation program with no program for patients before surgery. Results have not been reported yet, so we do not know if it helps.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over
- Where
- 1 site
The science
- Registered title
- Prehabilitation in Pancreatic Surgery
- Trial ID
- NCT06069297 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Pancreatic Cancer, Periampullary Cancer, Frailty Syndrome, Malnutrition, Perioperative/Postoperative Complications
- What is tested
- Multimodal Prehabilitation
- Sponsor
- IRCCS San Raffaele
- Ages
- 18 Years to no maximum
- Dates
- First posted Oct 5, 2023 · updated Aug 1, 2025
Registry summary
In patients with pancreatic cancer, older age, multiple comorbidities, frailty, malnutrition and poor functional status are common, especially in individuals receiving neoadjuvant chemotherapy. These characteristics represent potentially modifiable risk factors for poor postoperative outcomes.
The goal of this clinical randomized controlled trial is to evaluate the extent to which a four-week multimodal prehabilitation program impacts on postoperative morbidity, functional and nutritional status and health-related quality of life in patients with localized pancreatic or periampullary cancer scheduled for curative surgery.
In addition, the impact of prehabilitation on circulating sarcopenia and cancer cachexia biomarkers in PDAC patients will be explored.
Included patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation), which will receive prehabilitation, or to the control group, which will receive no prehabilitation.
Sites (1)
- San Raffaele Hospital, Milan, Lombardy, Italy